Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
British Journal of Cancer|March 22, 2007
Vascular disrupting agents in clinical developmentP Hinnen, F A L M EskensBritish Journal of Cancer|January 8, 2004
Angiogenesis inhibitors in clinical development; where are we now and where are we going?F A L M EskensDrugs of Today (Barcelona, Spain : 1998)|February 17, 2018
Tivozanib: a new treatment option for renal cell carcinomaL Saes, F A L M EskensExpert Opinion on Therapeutic Targets|September 12, 2007
Trial design for cancer (cell)-specific anticancer therapiesRobbert J van Alphen, J Verweij, F A L M EskensNederlands Tijdschrift Voor Geneeskunde|August 5, 2020
[As series of success stories; the pitfall of preoperative chemotherapy in unresectable carcinoma of the colon]E C T Geijteman, F A L M Eskens, H M WestgeestThe Netherlands Journal of Medicine|March 25, 2009
Systemic treatment in hepatocellular carcinoma; 'A small step for man...'C D M Witjes, C Verhoef, H M W Verheul, et al.British Journal of Cancer|November 27, 2008
The spliceosome as target for anticancer treatmentR J van Alphen, E A C Wiemer, H Burger, et al.British Journal of Cancer|April 18, 2007
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II studyE van Meerten, F A L M Eskens, E C van Gameren, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 20, 2020
A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcomeM A Teriaca, M Loi, M Suker, et al.European Journal of Cancer (Oxford, England : 1990)|April 23, 2003
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumoursF A L M Eskens, H Dumez, R Hoekstra, et al.Pageof 4